Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19
Covid19
About this trial
This is an interventional treatment trial for Covid19
Eligibility Criteria
Inclusion Criteria:
- Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology-Patient COVID type L (Criteria Gattinoni -CT Scan )
Exclusion Criteria:
- Patient COVID type H ( Gattinoni's Criteria -CT Scan )
- Patient's refusal or refusal of his legal representative
- HIV + AIDS
- Short life Expectancy
- Patients over 80 years of age.
- Patients under ECMO or ECCO2R
- Immunosuppression (steroids, chemotherapy…)
- Cancer
Sites / Locations
- CHU Brugmann
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control
Cytosorb
Standard medical therapy (ie: control group) : Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed……
CytoSorb therapy (ie: study group): Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed…… Plus patients will be on CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect. First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours. After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist.